

# Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetical epidemic situation in a middle-income country

Izquierdo, Giannina

Torres, Juan Pablo

Santolaya, M. Elena

Valenzuela, M. Teresa

Vega, Jeannette

Chomali, May

© 2015 Taylor & Francis Group, LLC. NmenB vaccine (4CMenB) is now available, but studies on the cost-effectiveness of vaccine introduction in a country outbreak situation are lacking. The aim of this study was to evaluate the cost-effectiveness of 4CMenB in the context of a hypothetical epidemic outbreak in Chile. We analyzed the direct and indirect costs of acute disease, sequelae and death for each case of meningococcal disease (MD) based on information obtained during the latest NmenB outbreak in Santiago, Chile, occurring between 1993-1999, with an incidence of 5.9/100,000 inhabitants and a mortality of 7.3%. We analyzed the cost of a mass vaccination campaign, considering one dose of 4CMenB for population between 12 months and 25 y of age and 3 doses for infants. Cost-effectiveness analysis was based on 80% and 92% 4CMenB immunogenicity for individual's below and over 12 months respectively. Sensitivity analysis was applied to different vaccine costs. Results: The total cost of t